Clinical data | |
---|---|
Other names | CI-628; CN-5518; CN-55945 |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H28N2O4 |
Molar mass | 444.531 g·mol−1 |
3D model (JSmol) | |
| |
|
Nitromifene (INN ; also as the citrate salt nitromifene citrate (USAN ), developmental code names CI-628, CN-5518, CN-55945) is a nonsteroidal selective estrogen receptor modulator (SERM) related to triphenylethylenes like tamoxifen that was never marketed.[1] It is a mixture of (E)- and (Z)-isomers that possess similar antiestrogenic activity.[2] The drug was described in 1966.[1] Along with tamoxifen, nafoxidine, and clomifene, it was one of the earliest SERMs.[3]
Nitromifene has been found to dissociate from the estrogen receptor 250-fold faster than estradiol.[4] This may be involved in its antagonistic activity at the estrogen receptor.[4]
References
- 1 2 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 880–. ISBN 978-1-4757-2085-3.
- ↑ Kirk RE, Othmer DF (1980). Encyclopedia of chemical technology. Wiley. p. 676. ISBN 978-0-471-02065-3.
- ↑ Jordan VC, Morrow M (June 1999). "Tamoxifen, raloxifene, and the prevention of breast cancer". Endocrine Reviews. 20 (3): 253–278. doi:10.1210/edrv.20.3.0368. PMID 10368771.
- 1 2 De Boer W, Notides AC, Katzenellenbogen BS, Hayes JR, Katzenellenbogen JA (January 1981). "The capacity of the antiestrogen CI-628 to activate the estrogen receptor in vitro". Endocrinology. 108 (1): 206–212. doi:10.1210/endo-108-1-206. PMID 7007019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.